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study
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Abstract
Background: PROMISE-2 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the
efficacy and safety of repeat intravenous (IV) doses of the calcitonin gene-related peptide–targeted monoclonal
antibody eptinezumab (ALD403) for migraine prevention in adults with chronic migraine. This report describes the
results of PROMISE-2 through 24 weeks of treatment.
Methods: Patients received up to two 30-min IV administrations of eptinezumab 100 mg, 300 mg, or placebo
separated by 12 weeks. Patients recorded migraine and headache endpoints in a daily eDiary. Additional
assessments, including patient-reported outcomes, were performed at regularly scheduled clinic visits throughout
the 32-week study period (screening, day 0, and weeks 2, 4, 8, 12, 16, 20, 24, and 32).
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Results: A total of 1072 adults received treatment: eptinezumab 100 mg, n = 356; eptinezumab 300 mg, n = 350;
placebo, n = 366. The reduction in mean monthly migraine days observed during the first dosing interval (100 mg,
− 7.7 days; 300 mg, − 8.2 days; placebo, − 5.6 days) was further decreased after an additional dose (100 mg, − 8.2
days; 300 mg, − 8.8 days; placebo, − 6.2 days), with both doses of eptinezumab demonstrating consistently greater
reductions from baseline compared to placebo. The ≥50% and ≥ 75% migraine responder rates (MRRs) increased
after a second dose, with more eptinezumab-treated patients experiencing migraine response than placebo
patients (≥50% MRRs weeks 13–24: 100 mg, 61.0%; 300 mg, 64.0%; placebo, 44.0%; and ≥ 75% MRRs weeks 13–24:
100 mg, 39.3%; 300 mg, 43.1%; placebo, 23.8%). The percentages of patients who improved on patient-reported
outcomes, including the Headache Impact Test and Patient Global Impression of Change, increased following the
second dose administration at week 12, and were greater with eptinezumab than with placebo at all time points.
No new safety concerns were identified with the second dose regarding the incidence, nature, and severity of
treatment-emergent adverse events.
Conclusion: Eptinezumab 100 mg or 300 mg administered IV at day 0 and repeated at week 12 provided sustained
migraine preventive benefit over a full 24 weeks and demonstrated an acceptable safety profile in patients with
chronic migraine.
Trial registration: ClinicalTrials.gov (Identifier: NCT02974153). Registered November 23, 2016.
Keywords: Eptinezumab, Chronic migraine, Efficacy, Safety
Background
Migraine, a highly prevalent neurological disorder, is char-
acterized by recurrent episodes of moderate to severe
headache associated with disruptions of neurological,
gastrointestinal and sensory function often recurring over
decades of life [1]. It is estimated that approximately 2.5%
of persons with migraine transform from episodic to
chronic migraine annually [2]. For those with chronic mi-
graine, headaches are generally more intense, migraine-
associated symptoms are more severe, and disease-related
impact and disability are much greater than episodic mi-
graine [3]. In addition, chronic migraine is associated with
more comorbid diseases, such as anxiety, arthritis, chronic
pain, and depression [4]. The high prevalence of migraine
and migraine-related disability, especially with chronic mi-
graine, is an important rationale for pursuing the develop-
ment of effective therapeutics for migraine prevention.
Eptinezumab (Vyepti™, Lundbeck Seattle BioPharma-
ceuticals, Inc., Bothell, WA, USA) is a humanized mono-
clonal antibody that inhibits calcitonin gene-related
peptide and was recently approved by the US Food &
Drug Association for preventive treatment of migraine in
adults. In the pivotal phase 3 PROMISE (PRevention Of
Migraine via Intravenous ALD403 Safety and Efficacy)
clinical trials of eptinezumab in patients with episodic mi-
graine [5] and chronic migraine [6], eptinezumab 100mg
and 300mg met the primary efficacy endpoints, with the
majority of treatment-emergent adverse events (TEAEs)
categorized as mild to moderate in severity.
The objective of this report is to describe the treat-
ment effects of eptinezumab 100 mg and 300 mg for the
prevention of chronic migraine over the full 24-week
treatment period of the pivotal PROMISE-2 trial.
PROMISE-2 was a phase 3, randomized, double-blind,
placebo-controlled study designed to evaluate the effi-
cacy, safety, and pharmacokinetics of repeat intravenous
(IV) doses of the eptinezumab for migraine prevention
in adults with chronic migraine. During the primary 12-
week treatment period of PROMISE-2—the results of
which have been published [6]—single doses of epti-
nezumab 100 mg and 300 mg were associated with
significant reductions in the primary endpoint (mean
monthly migraine days [MMDs]; p < 0.0001 vs pla-
cebo). Additionally, as a key secondary endpoint, the
percentage of patients with a migraine reduced by
over half on the day after the initial dose [6]. Both
doses (100 mg and 300 mg) were associated with sta-
tistically significant and clinically meaningful migraine




Study approval was provided by the independent ethics
committee or institutional review board at each study
site. The research was conducted in accordance with
current Good Clinical Practices as referenced in the
International Conference on Harmonization of Tech-
nical Requirements for Registration of Pharmaceuticals
for Human Use guidelines, the principles of the Declar-
ation of Helsinki, and local regulatory requirements. Be-
fore study initiation, each enrollee provided written
informed consent prior to their participation. This study
is registered on ClinicalTrials.gov under the following
identifier: NCT02974153.
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Study design and procedures
Full study details have been published previously, includ-
ing all inclusion and exclusion criteria [6]. Briefly,
PROMISE-2 was conducted at 128 study sites in 13
countries between November 30, 2016, and April 20,
2018. Eligible patients were aged 18 to 65 years (inclu-
sive), had a diagnosis of migraine at or before 50 years of
age, had a ≥ 12-month history of chronic migraine prior
to screening and, and experienced ≥15 to ≤26 headache
days, including ≥ 8 migraine days, during the 28-day
screening period (Fig. 1). Provided that dosages
remained stable for ≥3 months prior to screening, pre-
ventive medication was allowed. Patients with
medication-overuse headache (MOH) not associated
with opioid analgesics or barbiturates were eligible.
Eligible patients were assigned randomly (1:1:1) to re-
ceive eptinezumab 100mg, eptinezumab 300 mg, or pla-
cebo. Patient randomization was stratified by the
number of migraine days experienced in the baseline
period (≤17 days vs > 17 days) and by use of migraine
preventive medication within the 3-month period before
screening (use vs no use).
The entire study lasted 36 weeks and included scheduled
visits at screening, day 0, and weeks 2, 4, 8, 12, 16, 20, 24,
and 32. Patients received up to two IV doses of eptinezu-
mab (100mg or 300mg) or placebo, on day 0 and at week
12 (administered over 30min, plus another 15min [per
protocol, if required]). After completion of each dose, pa-
tients were monitored for at least two hours.
Outcome measures
The daily eDiary was used through week 24 to obtain a
daily report (irrespective of headache occurrence), and
to capture headache events and migraine days, as well as
acute use of medication. The start and end times for
headaches were captured. For this study, a “migraine
day” was defined as any day in which the patient had a
migraine, established using the eDiary. A migraine was
classified as lasting ≥4 h, or lasting 30 min to 4 h and be-
lieved by the patient to have been relieved by acute
medication; having ≥2 of the following characteristics:
unilateral location, pulsating quality, moderate or severe
pain intensity, and/or aggravation by or causing avoid-
ance of routine physical activity; and being accompanied
by ≥1 of the following: nausea and/or vomiting or photo-
phobia and phonophobia [1].
The primary efficacy endpoint (change from baseline
in MMDs for weeks 1 through 12) has been reported
[6]. In this analysis, mean change from baseline in
MMDs was evaluated through the 24-week treatment
period. Infusions of eptinezumab or placebo were pro-
vided at randomization and at the week 12 visit. Mi-
graine efficacy results over each dosing interval (12-week
period) were based upon the average number of MMDs
occurring during each associated 4-week period. If the
headache diary was completed for ≥21 days in a 4-week
period, the observed frequency was normalized to 28
days. If the diary was completed for < 21 days in a 4-
week period, the findings were a weighted function of
the observed data for the current interval and the results
for the previous interval, with the weight being propor-
tional to the number of completed days.
Migraine responder rates were defined as the number
of patients with a ≥ 50% and ≥ 75% reduction in MMDs
from their baseline. These reductions were based on the
reduction in the number of migraine days recorded in
the eDiary during the baseline period compared with the
average monthly number of migraine days recorded over
weeks 1–12 and weeks 13–24. For the 100% responder
endpoint, the 12-week 100% responder rate was the
average of 100% responder rates for the three 4-week in-
tervals. The 100% responder rate over weeks 13–24 was
calculated using a similar methodology, utilizing data
from weeks 13–16, 17–20, and 21–24.
Acute migraine medication days, defined as a day with
any triptan or ergot use as recorded in the eDiary, were
measured during the baseline period, and the mean
change during each dosing interval (weeks 1–12 and
13–24) was calculated.
During the scheduled follow-up visits, patients self-
reported different outcomes, including changes in their
self-selected most bothersome symptom (MBS), and
completed the 6-item Headache Impact Test (HIT-6 [7];
eptinezumab 300-mg group only), and the Patient Glo-
bal Impression of Change (PGIC) [8] scale. At screening,
patients described a MBS they associated with their
chronic migraine; from this information, the investigator
categorized the symptom into a predefined list, which
included nausea, vomiting, sensitivity to light, sensitivity
to sound, mental cloudiness, fatigue, pain with activity,
and mood changes. The list also included an “Other,
Specify” option for patient-identified symptoms that
were outside of the predefined list. At weeks 4, 8, 12, 16,
20, 24, and 32, patients were asked to rate the overall
change in that symptom since study initiation, using a
scale identical in design to the PGIC [8] scale. For both
scales, the seven possible responses were categorized as
“very much improved”, “much improved”, “minimally
Fig. 1 PROMISE-2 study design
Silberstein et al. The Journal of Headache and Pain          (2020) 21:120 Page 3 of 12
improved”, “no change”, “minimally worse”, “much
worse”, or “very much worse”. The HIT-6 v1.0 [7, 9]—
which has been validated in patients with chronic mi-
graine [10–12] —was administered at screening, day 0,
and each study visit through week 32. Scores of ≥60 de-
note severe life impact, 56–59 indicate substantial life
impact, 50–55 represent some life impact, and ≤ 49 dem-
onstrates little or no life impact [13]; full details of the
scoring system have been reported [6].
Safety was assessed throughout the study by monitor-
ing adverse events (AEs) and treatment-emergent AEs
(TEAEs), clinical laboratory tests, measuring vital signs,
performing physical examinations and 12-lead electro-
cardiograms, completing the Columbia-Suicide Severity
Rating Scale [14], and documenting concomitant medi-
cation use. TEAEs were classified according to the Med-
ical Dictionary for Regulatory Activities (MedDRA),
version 20.1.
Blood samples were collected at day 0 and weeks 2, 4,
8, 12, 24, and 32 to analyze pharmacokinetics and im-
munogenicity, which included monitoring for the devel-
opment of anti-drug antibodies (ADAs) and assaying for
neutralizing antibodies (NAbs).
Statistical methods
The power calculations for PROMISE-2 have been re-
ported [6]. All patients who received at least one dose of
study medication were included in the efficacy and safety
populations. For the safety analyses, results were sum-
marized by study treatment. Results for patients who re-
ceived two dose strengths for any reason were included
in the highest-dose treatment group. For efficacy ana-
lyses, results were summarized for each randomization
group.
A serial testing procedure was applied to account for
multiplicity associated with testing multiple dose
strengths and multiple endpoints. This procedure re-
sulted in statistical significance for all endpoints and
dose groups specified within the algorithm as reported
in the primary manuscript [6]. Additional endpoints
have been summarized here with descriptive statistics.
Alpha-controlled endpoints have been previously sum-
marized, and testing without alpha control has been
conducted for select predefined endpoints. Least squares
means from the ANCOVA model used to test the pri-
mary endpoint have been used to summarize the MMDs.
All analyses were conducted with SAS software (SAS In-
stitute, Cary, NC, USA) version 9.2 or higher.
Results
Patients
Patient disposition, as well as demographic and baseline
clinical characteristics, have been presented previously
[6]. A total of 1072 patients received treatment
(eptinezumab 100mg, n = 356; eptinezumab 300 mg, n =
350; placebo, n = 366) and were included in the efficacy
and safety populations. Most patients (1020/1072
[95.1%]) in the eptinezumab treatment arms received
both study infusions, including 340/356 (95.5%) in the
100 mg group and 338/350 (96.6%) in the 300 mg group.
Demographic and baseline clinical characteristics were
balanced across treatment groups [6]. Briefly, the total
patient population had a mean age of 40.5 years (stand-
ard deviation [SD], 11.2), with an average duration of
migraine diagnosis of 18.1 years (SD, 11.8) and average
duration of chronic migraine diagnosis of 11.8 years (SD,
11.2). Most patients were female (88.2%) and white
(91.0%). During the 28-day screening period, patients ex-
perienced an average of 20.5 headache days (SD, 3.1), in-
cluding 16.1 migraine days (SD, 4.6). A total of 1043
patients (97.3%) reported the use of ≥1 acute concomi-
tant headache medication and 479 (44.7%) reported the
use of ≥1 preventive concomitant headache medication;
rates were well balanced across treatment groups. A
total of 431 patients (40.2%) had a diagnosis of MOH
per ICHD-3β (39%, 42%, and 40% of the eptinezumab
100 mg, 300 mg, and placebo groups, respectively).
Migraine preventive efficacy
Efficacy outcomes for the two dosing intervals are sum-
marized in Table 1. Eptinezumab treatment significantly
reduced mean MMDs during the first dosing interval
(weeks 1–12) compared with placebo, with incremental
reductions observed during the second dosing interval
(weeks 13–24) across all treatment arms (Fig. 2a). Re-
ductions over 4-week intervals in MMDs were generally
sustained across the 24-week treatment period, with
eptinezumab 100 mg and 300 mg consistently resulting
in greater reduction from baseline compared with pla-
cebo (Fig. 2b). Over weeks 1–24, the mean change from
baseline in MMDs was − 7.9 for eptinezumab 100 mg, −
8.5 for 300mg, and − 5.9 for placebo (difference from
placebo: 100 mg, − 2.0 [95% CI: − 2.87, − 1.14]; 300 mg,
− 2.6 [95% CI: − 3.49, − 1.76]). Reductions in mean head-
ache days were consistent with the changes observed in
MMDs during this time period.
Eptinezumab 100 mg and 300 mg resulted in larger
percentages of patients achieving ≥50% reduction in
MMDs when compared with placebo across both dosing
intervals (Fig. 3a). During the first dosing interval, the
≥50% migraine responder rates were significantly greater
with eptinezumab (both doses), and this was sustained
during the second dosing interval across all treatment
groups. Post hoc analyses demonstrated that over 80% of
patients reported ≥50% fewer migraine days in at least
one 4-week interval, and approximately one-third of pa-
tients treated with eptinezumab (100 mg, 31.5%; 300 mg,
36.3%) were ≥ 50% migraine responders for the entire
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treatment period (i.e., in each 4-week interval from
Weeks 1 to 24) compared with 20.5% of patients who
received placebo (Fig. 3b). The odds ratio (versus pla-
cebo) of cumulative months with a ≥ 50% migraine re-
sponse was 1.974 (95% CI: 1.522, 2.561) for
eptinezumab 100 mg and 2.389 (95% CI: 1.836, 3.110)
for eptinezumab 300 mg.
The percentage of patients with a ≥ 75% reduction in
MMDs across the 2 dosing intervals was consistently
higher in the eptinezumab (100 mg and 300 mg) treat-
ment groups compared with placebo (Fig. 4a). During
the first dosing interval, the ≥75% migraine responder
rates were significantly greater than placebo, with similar
rate increases during the second dosing interval in all
Table 1 Efficacy outcomes (efficacy population)
Weeks 1–12 (Dose 1) Weeks 13–24 (Dose 2)
Eptinezumab
100mg n = 356
Eptinezumab




100mg n = 356
Eptinezumab





Mean 8.5 7.9 10.5 8.0 7.3 10.0
Change from baseline
Mean −7.7 −8.2 −5.6 −8.2 −8.8 −6.2
Difference from placebo −2.03 −2.60 − 1.98 −2.65
95% CI (−2.88, − 1.18) (− 3.45, − 1.74) (− 2.94, − 1.01) (− 3.62, − 1.68)
≥50% migraine responder rate
Patients, n (%) 205 (57.6) 215 (61.4) 144 (39.3) 217 (61.0) 224 (64.0) 161 (44.0)
Difference from placebo 18.2 22.1 17.0 20.0
95% CI (11.1, 25.4) (14.9, 29.2) (9.8, 24.1) (12.9, 27.2)
≥75% migraine responder rate
Patients, n (%) 95 (26.7) 116 (33.1) 55 (15.0) 140 (39.3) 151 (43.1) 87 (23.8)
Difference from placebo 11.7 18.1 15.6 19.4
95% CI (5.8, 17.5) (12.0, 24.3) (8.9, 22.2) (12.6, 26.2)
100% migraine responder rateb
Rate, % 10.8 15.1 5.1 17.8 20.8 9.3
Difference from placebo 5.8 10.1 8.5 11.5
95% CI (2.9, 8.6) (6.7, 13.4) (4.5, 12.5) (7.2, 15.7)
Monthly headache days
Actual
Mean 12.2 (6.68) 11.7 (6.96) 14.1 (6.38) 10.8 (7.42) 9.9 (7.44) 12.5 (7.25)
Change from baseline
Mean −8.2 (5.78) −8.8 (6.10) −6.4 (5.99) −9.6 (6.62) −10.6 (6.83) −8.1 (6.90)
Difference from placebo −1.7 −2.3 −1.5 −2.4
95% CI (−2.59, −0.87) (−3.22, −1.44) (−2.44, −0.47) (−3.43, −1.42)
Acute migraine medication daysc
Actual
Mean 3.3 (4.84) 3.2 (4.71) 4.3 (5.67) 3.2 (4.94) 2.8 (4.49) 4.0 (5.59)
Change from baseline
Mean −3.3 (4.89) − 3.5 (4.62) −1.9 (4.18) −3.4 (5.14) −3.9 (4.96) −2.2 (4.73)
Difference from placebo −1.2 −1.4 −1.1 −1.7
95% CI (−1.66, −0.65) (−1.88, −0.87) (−1.86, −0.42) (−2.44, −1.01)
aThe estimated mean, mean difference from placebo, and 95% confidence interval are from an analysis of covariance model, with treatment as a factor and the
stratification variables; baseline migraine days and preventive medication use as independent variables
bCalculated as the average percentage of patients with 100% migraine response for any given 4-week study month during the respective dosing interval
cDefined as a day with any triptan or ergot use as recorded in the eDiary
Abbreviations: CI confidence interval, MHD monthly headache day, MMD monthly migraine day, SD standard deviation
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treatment groups. Post hoc analyses demonstrated that
64–70% of patients achieved at least one 4-week interval
with a ≥ 75% reduction in monthly migraine frequency,
and approximately 13% and 17% of patients treated with
eptinezumab 100 mg and 300 mg, respectively, were ≥
75% migraine responders for all 4-week intervals
through Week 24 (compared with 46.7% and 5.7% of pa-
tients who received placebo, respectively) (Fig. 4b). The
odds ratio (versus placebo) of the cumulative number of
weeks with a ≥ 75% migraine response was 2.057 (95%
CI: 1.572, 2.691) for eptinezumab 100mg and 2.637
(95% CI: 2.012, 3.456) for 300 mg.
The percentage of patients with 100% monthly mi-
graine response ranged from 7.9% to 19.4% for eptinezu-
mab 100mg and 13.4% to 21.7% for eptinezumab 300
mg compared with 2.7% to 9.6% for placebo. During
each 4-week interval of the study, the percentage of pa-
tients with a 100% reduction in migraine days (i.e. pa-
tients with no migraines for a 4-week study month) was
higher in the eptinezumab groups than in the placebo
group (Fig. 5). The average of the 4-week 100% migraine
responder rate over weeks 1–12 was 10.8% for
eptinezumab 100 mg and 15.1% for eptinezumab 300
mg, compared with 5.1% for the patients who received
placebo. During the second dosing interval, the percent-
age of patients experiencing ≥4 weeks with 100% mi-
graine response increased to 17.8% with eptinezumab
100 mg, 20.8% with eptinezumab 300 mg, and 9.3% with
placebo.
In the 12-week analysis, both doses of eptinezumab
were associated with reduced acute migraine medication
days from baseline to week 12, which were greater than
the reduction associated with placebo—the difference
from placebo was − 1.2 days for the 100-mg dose and −
1.4 days for the 300-mg dose. As shown in Table 1, dur-
ing the second dosing interval (weeks 13–24) these dif-
ferences in the reduction of acute migraine medication
days were maintained or increased (difference from pla-
cebo was − 1.1 days for the 100-mg dose and − 1.7 days
for the 300-mg dose).
Impact of treatment on patient-reported outcomes
The effects of eptinezumab versus placebo on patient-
reported outcome measures are summarized in
Fig. 2 Reduction in mean monthly migraine days by (a) 12-week dosing interval and (b) 4-week interval (efficacy population). *P < 0.001 vs
placebo. †Nominal P < 0.001 vs placebo (analyses of monthly migraine days over weeks 13–24 were not formally tested per the predefined
statistical hierarchy)
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Supplementary Table 1. At baseline, based on HIT-6
total scores, 89.6%, 88.6%, and 87.4% of patients in the
eptinezumab 100mg, 300 mg, and placebo treatment
arms, respectively, had severe headache-related life im-
pact (i.e., a score of ≥60). The percentage of patients
with severe life impact dropped to 51.4% with eptinezu-
mab 100 mg and 42.9% with 300 mg compared with
60.1% in the placebo group at week 12. The percentage
of patients with severe life impact further decreased dur-
ing the second dosing interval, comprising 43.5%, 39.7%,
and 55.3% of patients in the eptinezumab 100mg, 300mg,
and placebo groups, respectively, by week 24. Correspond-
ingly, the percentages of patients with little to no
headache-related impact (HIT-6 total score ≤ 49) in-
creased from < 1% at baseline to 14.0% and 16.4% at week
12 and week 24, respectively, for eptinezumab 100mg and
from 1.1% to 16.6% and 23.6%, respectively, for 300mg.
For placebo, the corresponding percentages were 1.4% at
baseline, 9.6% at week 12, and 11.8% at week 24.
At week 12, more than half of eptinezumab-treated pa-
tients reported that their MBS was “much improved” or
“very much improved”: 53.5% with eptinezumab 100 mg,
61.2% with eptinezumab 300 mg; this compared with
34.1% with placebo. At week 24, results were similar:
eptinezumab 100mg, 56.8%; 300 mg, 62.4%; placebo,
39.3%. On the PGIC, 52.3% of patients treated with epti-
nezumab 100 mg and 63.8% treated with eptinezumab
300 mg indicated “much improved” or “very much im-
proved”, compared with 37.9% of placebo patients. PGIC
improvements at week 24 increased, similarly to patient-
identified MBS: eptinezumab 100 mg, 59.3%; 300 mg,
63.6%; placebo, 40.9%.
Adverse events
Full safety data across 24-weeks of treatment have been
presented previously [6]. Overall, 508 patients (47.4%)
experienced ≥1 TEAE during the study, and rates across
the treatment groups were similar. The percentages of
patients experiencing any TEAE in the second dosing
interval were lower than in the first dosing interval
across all treatment groups (Table 2). TEAEs occurring
in ≥2% of patients in any treatment arm in either dosing
interval included nasopharyngitis, upper respiratory tract
infection, migraine, and nausea. During both dosing in-
tervals, TEAEs coded to hypersensitivity occurred in 3
patients (0.9%) treated with eptinezumab 300 mg.
Fig. 3 (a) Rates of ≥50% migraine response by 12-week dosing interval and (b) cumulative 4-week intervals with ≥50% migraine response
(efficacy population). *P < 0.001 vs placebo. †Nominal P < 0.001 vs placebo (analyses of migraine responder rates over weeks 13–24 were not
formally tested per the predefined statistical hierarchy)
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Immunogenicity
The ADA response profile was similar in patients receiv-
ing either the 100mg or 300 mg dose of eptinezumab.
Maximal ADA incidence occurred at week 24, corre-
sponding to 17.2% and 17.0% of treated patients in the
100 mg and 300 mg groups, respectively. ADA titers
were low across all groups, with no trend of increasing
titer related to dose. The ADA-positive incidence
declined following the 24-week time point, and by week
32 the ADA-positive responses decreased to 9.0% (29/321)
in the 300mg group and 11.4% (37/325) in the 100mg
group. The overall NAb-positive incidence was 6.4% (45/
706) of all eptinezumab-treated patients, with 26 patients
treated with 100mg and 19 patients treated with 300mg
having ADA-positive results with neutralizing potential.
As indicated in the primary report [6], the development of
ADA, including NAb, had no impact on the safety or effi-
cacy outcomes with eptinezumab treatment.
Patients (66/646) who tested positive for anti-
eptinezumab antibodies at the end-of-study visit (week
32) continued immunogenicity testing at approximately
12-week intervals for up to 24 weeks (i.e. follow-up
visits) to evaluate persistence of the ADA response. At
the 12-week follow-up visit, 60 ADA-positive patients
were available for analysis, of whom 15 remained posi-
tive; of these, 5 had neutralizing antibodies. At the 24-
week follow-up visit, 13 ADA patients were available; of
these, 7 remained ADA-positive. Only 1 of these patients
had neutralizing antibody. The number of ADA-positive
subjects at the 12-week follow-up analysis were similar
across the eptinezumab 100 mg and 300 mg dose groups,
and the ADA responses at both the 12- and 24-week
Fig. 4 (a) Rates of ≥75% migraine response by 12-week dosing interval and (b) cumulative 4-week intervals with ≥75% migraine response
(efficacy population). *P≤ 0.001 vs placebo
Fig. 5 Rates of 100% migraine response by 4-week interval (efficacy
population). †Nominal P < 0.001 vs placebo (analyses of migraine
responder rates over weeks 13–24 were not formally tested per the
predefined statistical hierarchy)
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follow-up visits showed low titers (≤450) with a steady
decline over time.
Discussion
In this analysis of both 12-week treatment periods of the
PROMISE-2 study, the magnitude of efficacy that eptine-
zumab achieved during the first dosing interval was sus-
tained through 24 weeks, including both migraine-
preventive effects and improvements on patient-reported
outcomes. In addition, the temporal analysis of safety
did not identify any new safety concerns with an add-
itional dose.
Prior studies have shown that increased migraine fre-
quency is associated with higher levels of medication
usage, greater direct and indirect healthcare costs, and
lower work productivity [15, 16]. The observed reduc-
tions in migraine frequency in the PROMISE-2 study
could translate into decreased morbidity, reduced
healthcare resource utilization, and lower rates of absen-
teeism and presenteeism. From an average baseline of 16
monthly migraine days, eptinezumab-treated patients
had approximately 8 fewer migraine days each month on
average relative to baseline and approximately 2 days
fewer relative to placebo. The placebo effect observed in
PROMISE-2 may be due to the route of administration,
frequency of on-site visits, patient expectations and be-
liefs, or other contextual factors [17–20]. Despite the
placebo response, eptinezumab demonstrated statisti-
cally and nominally different improvements in migraine
frequency across 24 weeks of treatment.
The results for the reduction in monthly migraine days
reflects the 61%–64% of eptinezumab-treated patients
who experienced a ≥ 50% reduction in migraine com-
pared with the 44% of placebo patients. Notably, ap-
proximately one-third of eptinezumab-treated patients
reported a ≥ 50% reduction in migraine frequency over
the entire 24-week treatment period, which could sug-
gest the potential for remission from chronic migraine
depending a patient’s baseline MMDs. For those who ex-
perienced a ≥ 75% reduction in migraine frequency, the
reduction from the baseline average equates to 4 MMDs
or less. A consistent ≥75% migraine response (defined as
24 weeks of ≥75% reduction) was achieved by 13%–17%
of eptinezumab-treated patients compared with < 6% of
placebo patients. Lastly, the percentage of patients
treated with eptinezumab who experienced a 100% re-
duction in migraine increased as the study progressed;
placebo rates increased to a lesser degree.
Early reports suggested that eptinezumab improves pa-
tient functioning, as assessed by patient-reported outcome
measures [21, 22]. In a phase 2b dose-ranging study in pa-
tients with chronic migraine, mean HIT-6 scores im-
proved by 6.9 in the eptinezumab 100mg group and 10.0
in the 300mg group versus 5.8 for the placebo group [22].
In the current study, the percentage of patients in the epti-
nezumab groups reporting severe headache-related life
impact (based on HIT-6 total scores) was decreased by ap-
proximately half at the week 12 and 24 visits, compared
with approximately 40% reduction with placebo patients.
At the other end of the HIT-6 spectrum, the percentage
of patients reporting little to no headache-related life im-
pact increased more in the eptinezumab groups than in
the placebo group at both week 12 and 24. Similar pat-
terns were observed in the patient-identified MBS and
PGIC measure, with ~ 60% of eptinezumab-treated pa-
tients reporting “much improved” or “very much im-
proved” at week 24 on each patient-reported outcome vs
~ 40% in the in the placebo group. While the PGIC mea-
sures patient-perceived improvements in disease status,
patient-identified MBS may be an additional determinant
of patient satisfaction that is not captured in other com-
mon patient-reported outcome measure or not associated
with reductions in MMDs. These findings show that re-
ductions in migraine frequency translate into meaningful
improvements in patients’ daily lives, allowing them to
more fully participate in daily activities such as those asso-
ciated with work, school, and/or social pursuits. Migraine
has an established negative impact on daily life and func-
tioning, with burdens placed on patients, as well as on
their families and caregivers [23–25]. Improvements in
functioning are, therefore, a key indicator of meaningful
day-to-day treatment benefit for patients.
Table 2 Treatment-emergent adverse events reported in ≥2% of patients in any treatment group by dosing interval (safety
population)



















Any event, n (%) 155 (43.5) 106 (29.8) 64 (18.4) 182 (52.0) 120 (34.3) 99 (28.8) 171 (46.7) 120 (32.8) 79 (22.2)
Nasopharyngitis 19 (5.3) 12 (3.4) 6 (1.7) 33 (9.4) 19 (5.4) 7 (2.0) 22 (6.0) 11 (3.0) 11 (3.1)
URTI 15 (4.2) 5 (1.4) 6 (1.7) 19 (5.4) 8 (2.3) 9 (2.6) 20 (5.5) 13 (3.6) 4 (1.1)
Migraine 6 (1.7) 1 (0.3) 4 (1.1) 8 (2.3) 2 (0.6) 4 (1.2) 16 (4.4) 6 (1.6) 7 (2.0)
Nausea 6 (1.7) 4 (1.1) 2 (0.6) 12 (3.4) 10 (2.9) 4 (1.2) 7 (1.9) 4 (1.1) 3 (0.8)
Dosing intervals were not mutually exclusive, meaning that a patient could be counted in both dosing intervals. Italics indicates ≥2% of patients for individual
events. URTI upper respiratory tract infection
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We have previously reported that eptinezumab signifi-
cantly reduced MMDs over weeks 1–12 after the first IV
administration, and this could be observed from as early
as day 1 following treatment [6]. Early onset and sus-
tained response during the PROMISE-2 study may be a
result of the pharmacokinetic properties of eptinezumab
and its route of administration. Maximum plasma con-
centrations are achieved immediately upon completion
of delivery of the IV administration and persist through-
out the dosing interval with a terminal elimination half-
life of 27 days [26, 27].
Eptinezumab was well tolerated throughout the 24
weeks of treatment, with no change in the safety profile
identified with a second dose. Due to the chronic nature
of chronic migraine, it would be expected that patients
eligible for preventive treatment would be repeatedly
dosed; therefore, it is important to understand any po-
tential cumulative effects of repeated exposure. Overall,
rates of TEAEs had no clear dose-response trend and
were generally similar to placebo across both dosing in-
tervals, demonstrating the safety and tolerability of re-
peated doses of eptinezumab in patients with migraine.
Of note is the lack of a safety signal with regard to con-
stipation and hypertension, two side effects which have
been reported in post-marketing surveillance studies of
other approved monoclonal antibodies targeting calci-
tonin gene-related peptide [28]. Adverse events are often
the reason for preventive treatment discontinuation [29];
therefore, continued good tolerability is important to
maintain persistence with therapy.
In previous eptinezumab studies the ADA response
was maximal at week 24 [5, 22] and declined thereafter.
The transient nature of the eptinezumab-associated
ADA response was demonstrated again in the current
study, with ADA-positive incidence declining after week
24 and through the end of the study (week 32), with no
observed effect on the efficacy or safety of eptinezumab
treatment. At the 12-week follow-up analysis, there were
no notable differences in the number of ADA-positive
patients between eptinezumab 100 mg and 300 mg dose
groups, indicating that persistence was not dose-related.
Study limitations
The current study was of sufficient duration to demon-
strate the efficacy of eptinezumab in patients with chronic
migraine, but the safety and durability of response over
prolonged periods of use remain to be fully evaluated. The
results of the open-label PREVAIL safety study (Clinical-
Trials.gov: NCT02985398), which examined the safety and
tolerability of long-term treatment with eptinezumab, will
be reported separately. Generalizability of the results of
this study is limited by the exclusion of certain patient
populations.
Conclusions
In adult patients with chronic migraine, eptinezumab
100 mg and 300 mg administered by 30-min IV on day 0
and at week 12 provided sustained migraine preventive
benefit over 24 weeks of treatment. In addition to the
majority (~ 60%) of eptinezumab-treated patients experi-
encing a ≥ 50% reduction in migraine frequency (and ~
40% experiencing a ≥ 75% reduction), treatment with
eptinezumab was associated with meaningful improve-
ments in patient-reported outcomes measuring
headache-related life impact, patient perception of dis-
ease, and patient-identified MBS. A second dose of epti-
nezumab did not result in any new safety signals,
including immunogenetic reactions. In conclusion, this
report provides further evidence that eptinezumab IV
can provide early and sustained migraine prevention and
improvements in patient functioning, with low risk of
adverse events.
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